EBF1 Antibody #50752
Filter:
- WB
- IP
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 65 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:100 |
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.
Protocol
Specificity / Sensitivity
EBF1 Antibody recognizes endogenous levels of total EBF1 protein. This antibody may detect nonspecific bands of unknown origin at 41 and 110 kDa. This antibody may cross-react with EBF2 and EBF3.
Species Reactivity:
Human
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly500 of human EBF1 protein. Antibodies are purified by peptide affinity chromatography.
Background
Early B-cell factor 1 (EBF1), also referred to as COE1, is a pioneering transcription factor that is crucial for defining B-cell lineage. In hematopoiesis, EBF1 promotes the expression of genes that specify B-cell lineage commitment, such as FoxO1, PAX5, and IRF-4, while also repressing the expression of transcription factor genes that promote alternate lineages (1,2). EBF1 has also been reported to play a role in olfactory neuronal cell, adipocyte, and early osteoclast differentiation (3-6). Due to the crucial role of EBF1 in B-cell development, mutations in EBF1 can lead to the development of B-cell acute lymphoblastic leukemia (B-ALL) (7,8). EBF1 expression is also suppressed in some solid tumor cancers, including genomic loss in breast cancer and down-regulation in pancreatic ductal adenocarcinomas (9,10). Lower expression levels of EBF1 also correlate with lower survival rates in patients with cholangiocarcinoma and colorectal carcinoma (CRC), and induced overexpression of EBF1 in CRC cell lines induces cell cycle arrest and apoptosis in vivo and in vitro (11,12).
- Miyai, T. et al. (2018) Genes Dev 32, 112-126.
- Li, R. et al. (2018) Genes Dev 32, 96-111.
- Tsai, R.Y. and Reed, R.R. (1997) J Neurosci 17, 4159-69.
- Wang, S.S. et al. (2004) Development 131, 1377-88.
- Akerblad, P. et al. (2005) Physiol Genomics 23, 206-16.
- Nieminen-Pihala, V. et al. (2021) Bone 146, 115884.
- Kuiper, R.P. et al. (2007) Leukemia 21, 1258-66.
- Mullighan, C.G. et al. (2007) Nature 446, 758-64.
- Neve, R.M. et al. (2006) Cancer Cell 10, 515-27.
- Jones, S. et al. (2008) Science 321, 1801-6.
- Armartmuntree, N. et al. (2018) Redox Biol 14, 637-644.
- Shen, Z. et al. (2020) Front Oncol 10, 1035.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.